Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 9/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510114 | 1.00 | CHEK2 (0.50) | CHEK2CHEK1ACP1MEN1KMT2A | |
| SCHEMBL4510123 | 1.00 | CHEK2 (0.50) | CHEK2CHEK1ACP1MEN1KMT2A | |
| SCHEMBL4521149 | 0.91 | CHEK2 (0.52) | CHEK2CHEK1ACP1MEN1KMT2A | |
| SCHEMBL4521155 | 0.91 | CHEK2 (0.52) | CHEK2CHEK1ACP1MEN1KMT2A | |
| SCHEMBL4521146 | 0.91 | CHEK2 (0.52) | CHEK2CHEK1ACP1MEN1KMT2A | |
| SCHEMBL4513025 | 0.90 | ACP1 (0.50) | ACP1MEN1KMT2ARXFP1EGFR | |
| SCHEMBL4503530 | 0.90 | ACP1 (0.50) | CHEK2ACP1MEN1KMT2ARXFP1 | |
| SCHEMBL4513028 | 0.90 | ACP1 (0.50) | ACP1MEN1KMT2ARXFP1EGFR | |
| SCHEMBL4503522 | 0.90 | ACP1 (0.50) | CHEK2ACP1MEN1KMT2ARXFP1 | |
| SCHEMBL4503519 | 0.90 | ACP1 (0.50) | CHEK2ACP1MEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | CHEK2 606/4885CHEK1 1030/4885ACP1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.